Evidence map›Paper›PMID 23590231›Full record

ArticleJournal of the American Geriatrics Society2013

Pharmacotherapeutic management of dementia across settings of care.

Gail B Rattinger, Mehmet Burcu, Sarah K Dutcher, Pankdeep T Chhabra, Paul B Rosenberg, Linda Simoni-Wastila, Christine S Franey, Loreen D Walker, Ilene H Zuckerman

Abstract readComparative StudyMulticenter Study
In one paragraph

Article in Journal of the American Geriatrics Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gail B RattingerPharmaceutical Health Services Research Department, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA. gratting@rx.umaryland.edu
Mehmet Burcu
Sarah K Dutcher
Pankdeep T Chhabra
Paul B Rosenberg
Linda Simoni-Wastila
Christine S Franey
Loreen D Walker
Ilene H Zuckerman

Funding

RESEARCH TRAINING IN THE EPIDEMIOLOGY OF AGINGT32AG000262 · NIA · UNIVERSITY OF MARYLAND BALTIMORE · PI ANN L GRUBER-BALDINI, DENISE L ORWIG · 1998 to 2026
$8.2M
Maryland's Organized Research Effort in Women's Health (MORE-WH)K12HD043489 · NICHD · UNIVERSITY OF MARYLAND BALTIMORE · PI TRACY, J. KATHLEEN · 2002 to 2016
$7.0M
NIA NIH HHS T32 AG000262NIA NIH HHS T32AG000262NICHD NIH HHS K12 HD043489
6 · The paper itself

Abstract

objectivesTo describe population-based use of cognitive-enhancing and psychopharmacological medications across care settings in Medicare beneficiaries with dementia.

designOne-year (2008) cross-sectional study.

settingMedicare administrative claims from a 5% random sample.

participantsMedicare beneficiaries with dementia aged 65 and older with continuous Medicare Parts A, B, and D coverage and alive throughout 2008. To ascertain dementia, one or more medical claims with a dementia International Classification of Diseases, Ninth Revision, Clinical Modification code was required before 2008, and an additional claim was required in 2008 to confirm active disease. MEASUREMENTS: Use of medications commonly prescribed in managing dementia (cognitive enhancers, antidepressants, antipsychotics, and mood stabilizers) was assessed using three measures: annual prevalence of use, consistency of use, and count of psychopharmacological medication classes. Care setting was determined using the number of months of nursing home (NH) residency: no NH (0 months), partial NH (1-11 months), and full NH (12 months).

resultsCommunity-dwellers represented 41.3% of the cohort, whereas 42.4% and 16.3% resided partially and fully in a NH, respectively. Annual prevalence of use was 57.1% for cognitive enhancers, 56.4% for antidepressants, 34.0% for antipsychotics, and 8.8% for mood stabilizers. Cognitive enhancer use was significantly lower in those with any NH stay (partial NH vs no NH, adjusted prevalence ratio (APR) = 0.84, 99% confidence interval (CI) = 0.83-0.86; full NH vs no NH, APR = 0.83, 99% CI = 0.81-0.85). In contrast, those with any NH residence had significantly higher use of all psychopharmacological medication classes than community-dwellers. More than half the cohort had consistent medication regimens during 2008 (64.8%). The number of psychopharmacological medication classes used increased with increasing NH stay duration.

conclusionThis population-based study documents significant differences in medication use for managing dementia between care settings and substantial use of psychopharmacological medications in older adults with dementia.

Indexed as

AgedAged, 80 and overAntipsychotic AgentsCross-Sectional StudiesDementiaFemaleFollow-Up StudiesHumansMaleMedicarePrescription DrugsPrevalenceRetrospective StudiesUnited StatesAntipsychotic AgentsPrescription Drugs

Identifiers

PMID23590231
PMCPMC3656151

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.